Search Results

Press Releases

Bial Launches KYNMOBI® (Apomorphine Hydrochloride) in the United Kingdom

January 7, 2026

·

8 min read

Press Releases

Bial Achieves Key Milestone in Phase 2b ACTIVATE Study of BIA 28-6156 in GBA1-Associated Parkinson’s Disease

January 27, 2026

·

4 min read

Press Releases

BIAL Announces Oral Presentation at GBA1 Meeting 2025

June 3, 2025

·

3 min read

Pharm Country

Amneal and BIAL Announce U.S. Licensing Agreement for ONGENTYS® (opicapone)

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal”) and BIAL - Portela & Ca., S.A. (“BIAL”), today announced a licensing agreement where Amneal will have exclusive rights to market and distribute ONGENTYS® (opicapone) in the U.S. starting on December 18, 2023.

December 7, 2023

·

13 min read

Press Releases

BIAL Announces First Patient Out in its Phase 2 Clinical Trial of BIA 28-6156 - a Novel Therapy for GBA1 Parkinson’s Disease

January 7, 2025

·

5 min read

Drug Development

BIAL R&D Announces First Patient Dosed in its Phase 2 Clinical Trial of BIA 28-6156 to Treat Parkinson’s Disease Patients With a Pathogenic Variant in the Glucocerebrosidase (GBA1) Gene

BIAL - R&D Investments S.A (BIAL R&D), a subsidiary of BIAL Holding, S.A., today announced the dosing of the first patient in its Phase 2 clinical trial (ACTIVATE study) to evaluate the efficacy, safety, and tolerability of BIA 28-6156.

May 25, 2023

·

4 min read

Business

Sunovion and BIAL Enter European Licensing Agreement for Apomorphine Sublingual Film for the Treatment of Parkinson’s Disease OFF Episodes

Sunovion Pharmaceuticals Inc. (Sunovion) today announced that it has entered into an agreement with BIAL in which Sunovion has granted exclusive commercial license rights in Europe for apomorphine sublingual film (APL-130277)

September 2, 2021

·

11 min read

Genetown

BIAL Goes Global With New US Research Center and Acquisition of Promising Parkinson’s Disease Programs

BIAL Biotech to be based in Cambridge, Massachusetts and will be a Research Center of Excellence dedicated to genetically-defined Parkinson’s disease

October 1, 2020

·

4 min read

Press Releases

Key Milestone in ACTIVATE Phase 2 Clinical Trial of BIA 28-6156

October 2, 2025

·

3 min read

Business

BIAL and Wanbang Announce Exclusive Licensing Agreement for Opicapone in China

Under the terms of the agreement, BIAL will receive from Wanbang an upfront license fee of 2.5 million euros and up to 12.5 million euros in further milestones.

January 9, 2018

·

2 min read